Shared more. Cited more. Safe forever.
    • advanced search
    • submit works
    • about
    • help
    • contact us
    • login
    View Item 
    •   MOspace Home
    • University of Missouri-Columbia
    • School of Medicine (MU)
    • Department of Family and Community Medicine (MU)
    • Family Physicians Inquiries Network (MU)
    • Clinical Inquiries (MU)
    • Clinical Inquiries, 2006
    • View Item
    •   MOspace Home
    • University of Missouri-Columbia
    • School of Medicine (MU)
    • Department of Family and Community Medicine (MU)
    • Family Physicians Inquiries Network (MU)
    • Clinical Inquiries (MU)
    • Clinical Inquiries, 2006
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    advanced searchsubmit worksabouthelpcontact us

    Browse

    All of MOspaceCommunities & CollectionsDate IssuedAuthor/ContributorTitleIdentifierThesis DepartmentThesis AdvisorThesis SemesterThis CollectionDate IssuedAuthor/ContributorTitleIdentifierThesis DepartmentThesis AdvisorThesis Semester

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular AuthorsStatistics by Referrer

    What is the best medical therapy for new-onset type 2 diabetes?

    Klam, Cheri
    Neher, Jon O.
    Mayo, Helen G.
    View/Open
    [PDF] WhatTherapyNewOnsetType2.pdf (142.7Kb)
    Date
    2006
    Format
    Article
    Metadata
    [+] Show full item record
    Abstract
    Sulfonylureas, metformin, thiazolidinediones, and non-sulfonylurea secretagogues differ little in their ability to decrease glycosylated hemoglobin (HbA1c) levels when used as initial monotherapy for diabetes mellitus type 2 (strength of recommendation [SOR]: A, based on systematic reviews); α-glucosidase inhibitors may also be as effective (SOR: B, based on systematic reviews with inconsistent results). Metformin is generally indicated in obese patients because it improves all-cause mortality and diabetes related outcomes (SOR: B, based on a single high-quality randomized controlled trial [RCT]). Insulin is generally not recommended as an initial agent (SOR: C, expert opinion).
    URI
    http://hdl.handle.net/10355/3576
    Part of
    Journal of family practice, 55, no. 11 (November 2006): 1001-1003
    Rights
    OpenAccess.
    This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.
    Collections
    • Clinical Inquiries, 2006

    Send Feedback
    hosted by University of Missouri Library Systems
     

     


    Send Feedback
    hosted by University of Missouri Library Systems